NASDAQ:DBVTDBV TECHNOLOGIE/S Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding DBV TECHNOLOGIE/S Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $4.49 +0.10 (+2.28 %) (As of 07/2/2020 04:00 PM ET) Add Compare Share Today's Range$4.38Now: $4.49▼$4.6150-Day Range$4.49MA: $5.10▼$5.9352-Week Range$2.02Now: $4.49▼$13.49Volume207,300 shsAverage Volume221,150 shsMarket Capitalization$493.23 millionP/E RatioN/ADividend YieldN/ABeta2.67 ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunotherapy product, which has completed Phase III clinical trial for the treatment of peanut allergies in children, adolescents, and adults. The company is also developing Viaskin Milk that is in Phase II clinical trial for the treatment of Immunoglobulin E mediated cow's milk protein allergy (CMPA) and milk-induced eosinophilic esophagitis; Viaskin Egg, a pre-clinical stage product for the treatment of hen's egg allergy; and booster vaccine for Bordatella pertussis. Its other earlier stage research programs include vaccine for respiratory syncytial virus, as well as treatments for Crohn's disease, hemophilia A, celiac disease, and type I diabetes. The company has collaboration with Nestlé Health Science to develop MAG1C, an atopy patch test for the diagnosis of CMPA in infants and toddlers. DBV Technologies S.A. was founded in 2002 and is headquartered in Montrouge, France.Read More Beat the Market (BTM) Rank™ 3.3 Analyst's Opinion Consensus RatingDBV TECHNOLOGIE/S has received a consensus rating of Buy. The company's average rating score is 2.50, and is based on 4 buy ratings, 4 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $11.00, DBV TECHNOLOGIE/S has a potential upside of 145.0% from its current price of $4.49.Amount of Analyst CoverageDBV TECHNOLOGIE/S has only been the subject of 2 research reports in the past 90 days. Previous Next 2.4 Community Rank Outperform VotesDBV TECHNOLOGIE/S has received 374 “outperform” votes. (Add your “outperform” vote.)Underperform VotesDBV TECHNOLOGIE/S has received 398 “underperform” votes. (Add your “underperform” vote.)Community SentimentDBV TECHNOLOGIE/S has received 51.55% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about DBV TECHNOLOGIE/S and other stocks. Vote “Outperform” if you believe DBVT will outperform the S&P 500 over the long term. Vote “Underperform” if you believe DBVT will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldDBV TECHNOLOGIE/S does not currently pay a dividend.Dividend GrowthDBV TECHNOLOGIE/S does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, DBV TECHNOLOGIE/S insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 15.31% of the stock of DBV TECHNOLOGIE/S is held by insiders.Percentage Held by Institutions44.00% of the stock of DBV TECHNOLOGIE/S is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for DBV TECHNOLOGIE/S are expected to grow in the coming year, from ($2.13) to ($1.59) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of DBV TECHNOLOGIE/S is -1.93, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of DBV TECHNOLOGIE/S is -1.93, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioDBV TECHNOLOGIE/S has a P/B Ratio of 2.13. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.3Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.46 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:DBVT Previous Symbol CUSIPN/A CIK1613780 Webwww.dbv-technologies.com Phone33-1-55-42-78-78Debt Debt-to-Equity Ratio0.12 Current Ratio3.79 Quick Ratio3.75Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$14.75 million Price / Sales33.44 Cash FlowN/A Price / Cash FlowN/A Book Value$2.11 per share Price / Book2.13Profitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous Employees244 Outstanding Shares109,850,000Market Cap$493.23 million Next Earnings DateN/A OptionableOptionable NASDAQ:DBVT Rates by TradingView Receive DBVT News and Ratings via Email Sign-up to receive the latest news and ratings for DBVT and its competitors with MarketBeat's FREE daily newsletter. DBV TECHNOLOGIE/S (NASDAQ:DBVT) Frequently Asked Questions How has DBV TECHNOLOGIE/S's stock been impacted by COVID-19 (Coronavirus)? DBV TECHNOLOGIE/S's stock was trading at $7.08 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, DBVT stock has decreased by 36.6% and is now trading at $4.49. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of DBV TECHNOLOGIE/S? 8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for DBV TECHNOLOGIE/S in the last year. There are currently 4 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for DBV TECHNOLOGIE/S. How were DBV TECHNOLOGIE/S's earnings last quarter? DBV TECHNOLOGIE/S (NASDAQ:DBVT) posted its quarterly earnings data on Thursday, March, 26th. The company reported ($0.79) earnings per share for the quarter, missing analysts' consensus estimates of ($0.44) by $0.35. View DBV TECHNOLOGIE/S's earnings history. What price target have analysts set for DBVT? 8 analysts have issued twelve-month target prices for DBV TECHNOLOGIE/S's shares. Their forecasts range from $4.00 to $25.00. On average, they expect DBV TECHNOLOGIE/S's stock price to reach $11.00 in the next twelve months. This suggests a possible upside of 145.0% from the stock's current price. View analysts' price targets for DBV TECHNOLOGIE/S. Has DBV TECHNOLOGIE/S been receiving favorable news coverage? News coverage about DBVT stock has been trending somewhat negative on Friday, InfoTrie Sentiment Analysis reports. InfoTrie ranks the sentiment of media coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. DBV TECHNOLOGIE/S earned a news sentiment score of -1.0 on InfoTrie's scale. They also gave news stories about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the company's share price in the near future. View the latest news about DBV TECHNOLOGIE/S. Who are some of DBV TECHNOLOGIE/S's key competitors? Some companies that are related to DBV TECHNOLOGIE/S include Alector (ALEC), Bill.com (RVMD), Twist Bioscience (TWST), SpringWorks Therapeutics (SWTX), Editas Medicine (EDIT), Adverum Biotechnologies (ADVM), I-Mab (BDTX), Beam Therapeutics (BEAM), Cortexyme (CRTX), Regenxbio (RGNX), Sangamo Therapeutics (SGMO), Mesoblast (MESO), Sorrento Therapeutics (SRNE), Adaptimmune Therapeutics (ADAP) and Coherus Biosciences (CHRS). View all competitors. What other stocks do shareholders of DBV TECHNOLOGIE/S own? Based on aggregate information from My MarketBeat watchlists, some companies that other DBV TECHNOLOGIE/S investors own include Aimmune Therapeutics (AIMT), Opko Health (OPK), Bellicum Pharmaceuticals (BLCM), Axsome Therapeutics (AXSM), Five Prime Therapeutics (FPRX), Heron Therapeutics (HRTX), Novavax (NVAX), Amarin (AMRN), BioCryst Pharmaceuticals (BCRX) and Immunomedics (IMMU). Who are DBV TECHNOLOGIE/S's key executives? DBV TECHNOLOGIE/S's management team includes the following people: Dr. Pierre-Henri Benhamou, Co-Founder & Non-Exec. Chairman (Age 64)Mr. David Schilansky, Deputy CEO & CFO (Age 44)Dr. Laurent Martin, Chief Devel. Officer (Age 52)Mr. Daniel Tassé, CEO & Director (Age 59)Mr. Bertrand Dupont, Co-Founder & CTO (Age 67) What is DBV TECHNOLOGIE/S's stock symbol? DBV TECHNOLOGIE/S trades on the NASDAQ under the ticker symbol "DBVT." How do I buy shares of DBV TECHNOLOGIE/S? Shares of DBVT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is DBV TECHNOLOGIE/S's stock price today? One share of DBVT stock can currently be purchased for approximately $4.49. How big of a company is DBV TECHNOLOGIE/S? DBV TECHNOLOGIE/S has a market capitalization of $493.23 million and generates $14.75 million in revenue each year. The company earns $-172,020,000.00 in net income (profit) each year or ($2.33) on an earnings per share basis. DBV TECHNOLOGIE/S employs 244 workers across the globe. What is DBV TECHNOLOGIE/S's official website? The official website for DBV TECHNOLOGIE/S is www.dbv-technologies.com. How can I contact DBV TECHNOLOGIE/S? DBV TECHNOLOGIE/S's mailing address is 177-181 AVENUE PIERRE BROSSOLETTE, MONTROUGE I0, 92120. The company can be reached via phone at 33-1-55-42-78-78 or via email at [email protected] This page was last updated on 7/3/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
